Peptides Containing Saccharide Radicals, E.g., Bleomycins, Etc. Patents (Class 530/322)
  • Patent number: 10195288
    Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: February 5, 2019
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Takeshi Masuda, Hiroyuki Naito, Takashi Nakada, Masao Yoshida, Shinji Ashida, Hideki Miyazaki, Yuji Kasuya, Koji Morita, Yuki Abe, Yusuke Ogitani
  • Patent number: 10117952
    Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: November 6, 2018
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Takeshi Masuda, Hiroyuki Naito, Takashi Nakada, Masao Yoshida, Shinji Ashida, Hideki Miyazaki, Yuji Kasuya, Koji Morita, Yuki Abe, Yusuke Ogitani
  • Patent number: 10034893
    Abstract: In one aspect, the invention provides compounds represented by Formula I, and pharmaceutically acceptable salts, esters, stereoisomers, tautomers, solvates, and combinations thereof, pharmaceutical compositions comprising these compounds and the use of these compounds for treating a viral infection in a subject.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: July 31, 2018
    Assignee: ENANTA PHARMACEUTICALS, INC.
    Inventors: Jay R. Luly, Jun Ma, Guoqiang Wang, Yat Sun Or
  • Patent number: 9988673
    Abstract: A method for producing a nucleic acid molecule from a template nucleic acid sequence and a linking unit attached to a primer, which method comprises a step of contacting the template nucleic acid sequence with a nucleic acid polymerase under conditions which allow the nucleic acid polymerase to produce the nucleic acid molecule from the primer based on the template nucleic acid sequence, wherein the linking unit is attached to a target site in the template nucleic acid sequence with a covalent linkage.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: June 5, 2018
    Assignee: VILNIUS UNIVERSITY
    Inventors: Saulius Klimasauskas, Zdislav Stasevskij, Edita Kriukiene
  • Patent number: 9955705
    Abstract: The present invention pertains to a method of producing caseinomacropeptide (CMP)-containing compositions in high yield and having a very low content of phenylalanine (Phe). More specifically, the method involves subjecting a whey derived feed to a combination of ultrafiltration and subsequent cation exchange.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: May 1, 2018
    Assignee: ARLA FOODS AMBA
    Inventors: Jesper Christensen, Hans Henrik Holst
  • Patent number: 9950072
    Abstract: Controlled release dosage formulations for the delivery of one or more HIF-1 inhibitors are provided. The controlled release formulations contain one or more HIF-1 inhibitors conjugated to or dispersed in a polymeric vehicle. The one or more HIF-1 inhibitors can be dispersed or encapsulated in a polymeric matrix. In some embodiments, the one or more HIF-1 inhibitors are covalently bound to a polymer, forming a polymer-drug conjugate. Polymeric vehicles can be formed into implants, microparticles, nanoparticles, or combinations thereof. Controlled release HIF-1 formulations provide prolonged therapeutic benefit while lowering side effects by releasing low levels of one or more HIF-1 inhibitors and/or HIF-1 inhibitor conjugates over a prolonged period of time. Controlled release dosage formulations can be used to treat or prevent a disease or disorder in a patient associated with vascularization, including cancer, obesity, and ocular diseases such as wet AMD.
    Type: Grant
    Filed: January 19, 2015
    Date of Patent: April 24, 2018
    Assignee: The Johns Hopkins University
    Inventors: Justin Scot Hanes, Peter Anthony Campochiaro, Jie Fu
  • Patent number: 9872924
    Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula (I) is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- or -L1-L2-LP- wherein the antibody is connected to the terminal of L1, the antitumor compound is connected to the terminal of Lc or LP, and any one or two or more of linkers of L1, L2, and LP has a hydrophilic structure.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: January 23, 2018
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hiroyuki Naito, Takashi Nakada, Masao Yoshida, Shinji Ashida, Takeshi Masuda, Hideki Miyazaki, Yuji Kasuya, Yuki Abe, Yusuke Ogitani
  • Patent number: 9850469
    Abstract: The present disclosure pertains to the field peptide stapling and/or macrocyclization, where a structural motif is used to improve the properties of amino acid sequences (e.g. protease resistance, cellular penetration, biological activity). Also within the scope of the disclosure are methods for unstapling the S,S-tetrazine-containing amino acid sequence. The disclosure is also directed to methods for the reductive removal of thiocyanates from an amino acid sequence with cysteine to recycle back to the native amino acid sequence.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: December 26, 2017
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Amos B. Smith, III, Stephen Brown
  • Patent number: 9808537
    Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: November 7, 2017
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Takeshi Masuda, Hiroyuki Naito, Takashi Nakada, Masao Yoshida, Shinji Ashida, Hideki Miyazaki, Yuji Kasuya, Koji Morita, Yuki Abe, Yusuke Ogitani
  • Patent number: 9711789
    Abstract: A method for synthesizing lithium titanate includes preparing a supercritical fluid from water; reacting a solution containing lithium and titanium with the supercritical fluid under a condition that maintains the supercritical fluid in its supercritical state to produce a reaction mixture comprising the lithium titanate; and collecting the lithium titanate. The supercritical fluid is prepared at a temperature of 375-500° C. and a pressure of 22-35 MPa. The solution containing lithium and titanium is prepared by mixing a solution containing lithium, prepared by dissolving a lithium source in a selected solvent, and a solution containing titanium, prepared by dissolving a titanium source in the selected solvent, wherein a molar ratio of lithium:titanium is between 4.0:5.0 and 4.5:5.0. The lithium source is lithium hydroxide, lithium carbonate, lithium acetate, lithium oxalate, lithium nitrate, or lithium oxide, and the titanium source is tetrabutyl titanate.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: July 18, 2017
    Assignee: Hefei Guoxuan High-Tech Power Energy Co., Ltd.
    Inventors: Wenting Zhu, Maoping Yang, Xulai Yang, Xiaoming Xu, Jia Xie, Zhen Li
  • Patent number: 9675671
    Abstract: Fusion proteins comprising cytokines, particularly insulin-like growth factor-1 (IGF-1) and variants thereof, epidermal growth factor (EGF), and other ligands to the EGF receptor, are provided. The fusion proteins further comprise SEQ ID NO:1 or other segments having lysine, glutamic acid, or aspartic acid residues. Uses for the fusion proteins are also provided.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: June 13, 2017
    Assignee: IGF Oncology, LLC
    Inventor: Hugh McTavish
  • Patent number: 9580511
    Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: February 28, 2017
    Assignee: GENZYME CORPORATION
    Inventors: Clark Pan, Qun Zhou, James Stefano, Pradeep Dhal, Bo Chen, Diego Gianolio, Robert Miller, Huawei Qiu
  • Patent number: 9422357
    Abstract: [Problem] To provide a glycosylated polypeptide having an affinity to somatostatin receptors, and, compared to somatostatins, having improved in-blood stability. [Solution] The glycosylated polypeptide is characterized by at least one amino acid in a somatostatin or an analog thereof being replaced with a glycosylated amino acid.
    Type: Grant
    Filed: September 3, 2012
    Date of Patent: August 23, 2016
    Assignee: Glytech, Inc.
    Inventors: Hirofumi Ochiai, Taiji Shimoda, Kazuhiro Fukae, Masatoshi Maeda, Kazuyuki Ishii, Kenta Yoshida, Katsunari Tezuka, Keisuke Tazuru
  • Patent number: 9382294
    Abstract: The discovery of a non-ribosomal peptide synthetase (NRPS) gene cluster in the genome of Clostridium thermocellum that produces a secondary metabolite that is assembled outside of the host membrane is described. Also described is the identification of homologous NRPS gene clusters from several additional microorganisms. The secondary metabolites produced by the NRPS gene clusters exhibit broad spectrum antibiotic activity. Thus, antibiotic compounds produced by the NRPS gene clusters, and analogs thereof, their use for inhibiting bacterial growth, and methods of making the antibiotic compounds are described.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: July 5, 2016
    Assignee: Los Alamos National Security, LLC
    Inventors: Alexander Koglin, Matthias Strieker
  • Publication number: 20150147764
    Abstract: In a first aspect, there is provided an isolated polypeptide substrate for a disintegrin-like and metallopeptidase with thrombospondin type-1 motif, 13 (ADAMTS13) that is from 45 to 70 amino acids in length and has an amino acid sequence that is substantially similar to part of the von Willebrand factor A2 domain sequence set forth in SEQ ID NO:2, with one or more of the following modifications: (i) the amino acid corresponding to position 1599 of SEQ ID NO: 2 is mutated from Q to K; (ii) the amino acid corresponding to position 1610 of SEQ ID NO: 2 is mutated from N to C; and (iii) the amino acids corresponding to Q1624 to R1641 of SEQ ID NO: 2 are deleted.
    Type: Application
    Filed: November 9, 2012
    Publication date: May 28, 2015
    Inventors: Gian Paolo Visentin, Suzette Chance, Elizabeth Wuitschick
  • Publication number: 20150148410
    Abstract: An isolated peptidic fragment of apolipoprotein E comprises at least 3 contiguous amino acids, Including glycosylated threonine 194, threonine 289, serine 94, or serine 76 of SEQ ID NO.: 1, or any combination of those. An antibody capable of binding to the isolated peptidic fragment. A method of detecting a naturally-occurring circulating atherogenic low-density lipoprotein in a plasma sample from an individual, comprising qualitatively and/or quantitatively detecting in a low-density lipoprotein that binds to the antibody. A method of assessing an individual's risk of ischemic heart disease and/or atherosclerosis comprises quantifying in a plasma sample from the individual an amount of apolipoprotein E comprising glycosylated threonine 194, threonine 289, serine 94 or serine 76 of SEQ ID NO.: 1, or any combination of those.
    Type: Application
    Filed: September 10, 2012
    Publication date: May 28, 2015
    Applicant: Texas Heart Institute
    Inventors: Chu-Huang Chen, Liang-Yin Ke
  • Publication number: 20150141324
    Abstract: It is provided furin inhibitors and their uses for treating pathogen infection. Particularly, it is provided a method or use for the treatment of a pathogen infection, in a subject, comprising administering to the subject a therapeutically effective amount of the furin inhibitors or the composition disclosed, thereby preventing or treating pathogen infection, in the subject.
    Type: Application
    Filed: August 31, 2012
    Publication date: May 21, 2015
    Applicant: SOCPRA SCIENCES SANTE ET HUMAINES S.E.C.
    Inventors: Robert Day, Witold A. Neugebauer, Yves Dory
  • Publication number: 20150133631
    Abstract: An oligonucleotide derivative having the structure of formula (A) and methods for preparing the oligonucleotide derivative are disclosed. wherein R3 is a first oligonucleotide; R1 is selected from the group consisting of alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, a polyethylene glycol, a peptide, a protein, a polysaccharide, and a second oligonucleotide; R2 is a linker or a direct bond; Z1 is NR4, S, or O, and Z2 is NR4 or S, wherein R4 is selected from H, alkyl, aryl, heterocyclyl, or heteroaryl. A method includes: synthesizing an oligonucleotide derivative comprising an amino or thiol group; and reacting a 3,4-dialkoxycyclobutene-1,2-dione with the oligonucleotide derivative to produce an oligonucleotide-squarate mono-conjugate.
    Type: Application
    Filed: April 29, 2013
    Publication date: May 14, 2015
    Inventors: Kenneth W. Hill, Victor R Mokler
  • Publication number: 20150133362
    Abstract: Aspects of the invention provide methods for selecting a candidate oligonucleotide for activating expression of a target gene. Further aspects of the invention provide methods of selecting a set of oligonucleotides that is enriched in oligonucleotides that activate expression of a target gene. Further aspects provide single stranded oligonucleotides that modulate gene expression and compositions and kits comprising the same. Methods for modulating gene expression using the single stranded oligonucleotides are also provided.
    Type: Application
    Filed: May 16, 2013
    Publication date: May 14, 2015
    Applicants: RaNA Therapeutics, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
  • Publication number: 20150118178
    Abstract: Conjugates comprising a N-oxime bond are disclosed. In one embodiment, a suitable conjugate is represented by the following Formula (I): wherein R? is derived from a compound comprising at least one reactive amide group, R? is derived from a compound comprising at least one reactive aminooxy group, and X is H, CnH(n+2) or other atoms. Additional methods are also provided.
    Type: Application
    Filed: December 31, 2014
    Publication date: April 30, 2015
    Inventors: Cory Berkland, Joshua Sestak
  • Publication number: 20150119318
    Abstract: The present invention provides an isolated peptide having an amino acid residue sequence that comprises at least one human cytomegalovirus glycoprotein B (HCMV-gB) sequence segment, each HCMV-gB sequence segment consisting of at least 8 and not more than 60 consecutive amino acid residues from residues 146 to 315, residues 476 to 494 of SEQ ID NO: 1, or from a sequence variant of residues 146 to 315 or 476 to 494 of SEQ ID NO: 1 that has at least 70% sequence identity thereto. The peptides of the invention are useful for treating, preventing, or inhibiting a herpesvirus (e.g., Herpes Simplex Virus-1, Human Cytomegalovirus, and the like) infection in a subject.
    Type: Application
    Filed: July 9, 2014
    Publication date: April 30, 2015
    Applicant: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
    Inventors: Lilia I. Melnik, Robert F. Garry, Cindy A. Morris
  • Publication number: 20150110807
    Abstract: Polypeptides that bind to DC-SIGN and/or its homologues and methods for using such peptides for the treatment of various disorders are described. DC-SIGN and its homologues are receptors that bind IgG antibodies or Fc fragments and mediate intravenous immunoglobulin (IVIG)-related reversal of inflammation associated with various immune disorders.
    Type: Application
    Filed: December 10, 2012
    Publication date: April 23, 2015
    Applicants: The Rockefeller University, Sloan-Kettering Institute for Cancer Research
    Inventors: Jeffrey Ravetch, Andrew Pincetic, Ping Wang, Sam Danishefsky
  • Publication number: 20150112022
    Abstract: The present disclosure describes environmentally responsive polypeptides capable of displaying stimuli-triggered conformational changes in a reversible or irreversible manner that may be accompanied by aggregation. Polypeptides include a number of repeated motifs and may be elastomeric or non-elastomeric. The polypeptides may be used to deliver therapeutics to a biological site and to develop bioactive polypeptides that are environmentally responsive.
    Type: Application
    Filed: December 16, 2014
    Publication date: April 23, 2015
    Inventors: Ashutosh Chilkoti, Felipe Garcia Quiroz, Miriam Amiram
  • Publication number: 20150099658
    Abstract: The present application provides stable peptide-based anti-gp41 antibody capture agents and methods of use as detection and diagnosis agents. The application further provides methods of manufacturing anti-gp41 antibody capture agents using iterative on-bead in situ click chemistry.
    Type: Application
    Filed: September 12, 2014
    Publication date: April 9, 2015
    Inventors: Jessica A. Pfeilsticker, Aiko Umeda, James R. Heath
  • Publication number: 20150099698
    Abstract: Nanoparticles having a core and a corona of ligands covalently linked to the core, wherein differing species of peptides are bound to the nanoparticles and incorporated into various dosage forms.
    Type: Application
    Filed: October 8, 2013
    Publication date: April 9, 2015
    Inventors: Phillip Williams, Thomas Rademacher, Alexander Mark Schobel, Eric Dadey
  • Patent number: 8993737
    Abstract: In various embodiments, the present invention provides fluorescent dyes that are linked to another species through an amino acid or peptide linker. In an exemplary embodiment, the dye is linked to a polyphosphate nucleic acid through an amino acid or peptide linker. These conjugates find use in single molecule DNA sequencing and other applications. In various embodiments, the dye moiety is a cyanine dye. Cyanine dyes that are highly charged, such as those including multiple sulfonate, alkylsulfonate, carboxylate and/or alkylcarboxylate moieties are examples of cyanine dyes of use in the compounds of the invention.
    Type: Grant
    Filed: August 25, 2011
    Date of Patent: March 31, 2015
    Assignee: Pacific Biosciences, Inc.
    Inventor: Gene Shen
  • Publication number: 20150087806
    Abstract: A glycolipopeptide comprising a carbohydrate component, a peptide component and a lipid component, for use as a therapeutic or prophylactic vaccine. Also provided are monoclonal and polyclonal antibodies that recognize the glycolipopeptide of the invention, as well as uses thereof.
    Type: Application
    Filed: December 2, 2014
    Publication date: March 26, 2015
    Applicant: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
    Inventors: GEERT-JAN BOONS, THERESE BUSKAS, SAMPAT INGALE, MARGARETHA WOLFERT
  • Publication number: 20150080313
    Abstract: The subject of the present invention is pharmaceutical composition containing active ingredients in the form of a peptide of the myelin basic protein, a peptide from the myelin protein and oligodendrocytes as well as a peptide of the proteolipid protein as well as the use of the composition in the manufacturing of a drug for topical administration in the treatment of the disease multiple sclerosis. The composition may be administered topically.
    Type: Application
    Filed: February 8, 2013
    Publication date: March 19, 2015
    Inventors: Krzysztof SELMAJ, Marian SZCZEPANIK
  • Publication number: 20150080318
    Abstract: A compound of the general formula (III): wherein X is O, S, NH or CH2; Y is O, S or NH; Z is O, S or CH2; R1 is C1-8 alkyl, especially C1-6 alkyl, preferably n-alkyl, e.g., n-pentyl or n-hexyl; at least one of R2 and R3 is H—[R4-R5]n—R6—, in which: H—[R4-R5]n— comprises an oligopeptide, R4 being an amino acid and R5 being an amino acid selected from proline, alanine, hydroxyproline, dihydroxyproline, thiazolidinecarboxylic acid (thioproline), dehydroproline, pipecolic acid (L-homoproline), azetidinecarboxylic acid, aziridinecarboxylic acid, glycine, serine, valine, leucine, isoleucine and threonine, R6 is a neutral, non-polar amino acid moiety that is bonded to R5 by a peptide bond, and n is 1, 2, 3, 4 or 5; and the other of R3 and R2 is H—[R4-R5]n—R6— or H; or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 19, 2014
    Publication date: March 19, 2015
    Inventors: Jan Balzarini, Maria Jose Camarasa, Sonsoles Velazquez
  • Publication number: 20150079125
    Abstract: The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to bacterial polysaccharides conjugated to protein D from H. influenzae.
    Type: Application
    Filed: November 21, 2014
    Publication date: March 19, 2015
    Inventors: Carine CAPIAU, Marguerite DESCHAMPS, Pierre Michel DESMONS, Craig Antony Joseph LAFERRIERE, Jan POOLMAN, Jean-Paul PRIEELS
  • Publication number: 20150080311
    Abstract: An antisense compound for use in treating myotonic dystrophy DM1 or DM2, a method of enhancing antisense targeting to heart and quadricep muscles, and a method for treating DM1 or DM2 in a mammalian subject are disclosed. The oligonucleotide has 8-30 bases, with at least 8 contiguous bases being complementary to the polyCUG or polyCCUG repeats in the 3?UTR region of dystrophia myotonica protein kinase (DMPK) mRNA in DM1 or DM2, respectively. Conjugated to the oligonucleotide is a cell-penetrating peptide having the sequence (RXRR(B/X)R)2XB, where R is arginine; B is ?-alanine; and each X is —C(O)—(CH2)n—NH—, where n is 4-6. The antisense compound is effective to selectively block the sequestration of muscleblind-like 1 protein (MBNL1) and/or CUGBP, in heart and quadricep muscle in a myotonic dystrophy animal model.
    Type: Application
    Filed: April 24, 2014
    Publication date: March 19, 2015
    Applicant: Sarepta Therapeutics, Inc.
    Inventors: Hong M. Moulton, Ryszard Kole
  • Patent number: 8981050
    Abstract: The present invention relates to methods for producing N-terminal derivatives of proteins in which a polysaccharide, preferably having at least terminal sialic units and preferably consisting essentially only of sialic acid units, is reacted at the N-terminus of a protein or peptide under controlled conditions to produce an N-terminal derivative. The controlled conditions include use of acidic pH for the derivatization step and a higher pH for purification. The derivatives are useful for improving pharmacokinetics and pharmacodynamics of proteins and peptides.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: March 17, 2015
    Assignee: Lipoxen Technologies Limited
    Inventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis
  • Patent number: 8975079
    Abstract: Provided herein are biodegradable copolymers and nanoplex delivery systems comprising the same and a cargo molecule, such as a nucleic acid, a polynucleotide or other biomolecule. The biodegradable copolymers may comprise a reducible polymer linearly modified with lysine, such as a linear lysine-modified N,N?-cystamine bisacrylamide. The biodegradable copolymers also may be conjugated to a sequestering moiety, such as dietheylamine. The biodegradable copolymers also may comprise one or both of a targeting moiety and one or more moieties to facilitate endosomal escape. Also provided are methods for treating a pathophysiological condition and for increasing biocompatibility of a polymeric delivery system upon delivery to a subject using the biodegradable copolymers and nanoplexes.
    Type: Grant
    Filed: February 11, 2010
    Date of Patent: March 10, 2015
    Assignee: University of Houston System
    Inventor: Malavosklish Bikram
  • Publication number: 20150051371
    Abstract: Provided herein are water-soluble carbohydrate polymers which are monoderivatized at their reducing terminus, such that the carbohydrate polymers can be selectively conjugated at a single location. Also provided are methods of preparation and conjugation of the monoderivatized carbohydrate polymers.
    Type: Application
    Filed: January 29, 2014
    Publication date: February 19, 2015
    Applicant: NEKTAR THERAPEUTICS
    Inventors: Antoni Kozlowski, Samuel P. McManus, Xiaoming Shen
  • Patent number: 8957016
    Abstract: The instant invention provides compositions comprising a prodrug, the prodrug comprising a therapeutically active drug; and a peptide selected from the group consisting of the sequences: Ser-Ser-Lys-Tyr-Gln (SEQ ID NO:1); Gly-Lys-Ser-Gln-Tyr-Gln (SEQ ID NO:2); and Gly-Ser-Ala-Lys-Tyr-Gln (SEQ ID NO:3) wherein the peptide is linked to the therapeutically active drug to inhibit the therapeutic activity of the drug, and wherein the therapeutically active drug is cleaved from the peptide upon proteolysis by an enzyme having a proteolytic activity of prostate specific antigen (PSA). The invention further provides methods of making and using the claimed compositions.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: February 17, 2015
    Inventors: Samuel R. Denmeade, John T. Isaacs
  • Publication number: 20150045506
    Abstract: A method for producing a polypeptide, includes at least one native ligation step using a peptide functionalized with a selenium group. The selenium peptides and compounds are also described.
    Type: Application
    Filed: March 18, 2013
    Publication date: February 12, 2015
    Applicants: UNIVERSITE LILLE 2 DROIT ET SANTE, INSTITUT PASTEUR DE LILLE
    Inventors: Oleg Melnyk, Laurent Raibaut, Nathalie Ollivier
  • Publication number: 20150038429
    Abstract: The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides having a hydrolyzable covalent bond to a therapeutic agent that includes, etoposide, etoposide 4?-dimethylglycine or doxorubicin. These polypeptide conjugates can be used as vectors to transport the podophyllotoxin derivative across the blood brain barrier (BBB) or into particular cell types such as ovary, liver, lung, or kidney. The invention also relates to pharmaceutical compositions that include the compounds of the invention and to uses thereof in methods of treatment.
    Type: Application
    Filed: July 11, 2014
    Publication date: February 5, 2015
    Inventors: Michel DEMEULE, Christian Che, Reinhard Gabathuler, Gaoqiang Yang
  • Patent number: 8946144
    Abstract: The present invention is directed to antimicrobial compounds which have an affinity for binding bones. More particularly, the invention is directed to phosphonated derivatives of glycopeptide or lipoglycopeptide antibiotics. These compounds are useful as antibiotics for the prevention or treatment of bone and joint infections, especially for the prevention and treatment of osteomyelitis.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: February 3, 2015
    Assignee: The Medicines Company
    Inventors: Kelly Tanaka, Stephane Ciblat, Adel Rafai Far, Evelyne Dietrich
  • Publication number: 20150031619
    Abstract: This invention relates to collagen-binding synthetic peptidoglycans and engineered collagen matrices comprising a collagen matrix and a collagen-binding synthetic peptidoglycan where the collagen-binding synthetic peptidoglycan can be aberrant or can have amino acid homology with a portion of the amino acid sequence of a protein or a proteoglycan that regulates collagen fibrillogenesis. The invention also relates to kits, compounds, compositions, and engineered graft constructs comprising such collagen-binding synthetic peptidoglycans or engineered collagen matrices and methods for their preparation and use.
    Type: Application
    Filed: August 22, 2014
    Publication date: January 29, 2015
    Inventors: Alyssa Panitch, John E. Paderi, Kinam Park, Katherine Stuart, Steve Higbee
  • Publication number: 20150031755
    Abstract: The present invention is related to a nucleic acid molecule capable of binding to CGRP, wherein the nucleic acid molecule comprises a central stretch of nucleotides, wherein the central stretch of nucleotides comprises a nucleotide sequence of 5? HWn1n2YGGAn3An4UMn5n6Yn7n8n9n10n11Kn12Rn13ADn14n15 ARn16Un17Cn18n19Un20n21 3? [SEQ ID NO: 99], wherein H, W, Y, G, A, U, M, B, K, R, D, C are ribonucleotides, and n1 is R or dG, n2 is U or dT, n3 is K or dG, n4 is C or dC, n5 is M or dC, n6 is B or dU, n7 is N or dG, n8 is Y or dT, n9 is N or dC, n10 is R or dG, n11 is V or dA, n12 is K or dT or dU, n13 is G or dG, n14 is A or dA, n15 is U or dT, n16 is R or dG, n17 is Y or dC, n18 is C or dC, n19 is B or dC, n20 is C or dC, n21 is C or dC, and dG, dT, dC, dA and dU are 2?-deoxyribonucleotides.
    Type: Application
    Filed: January 10, 2013
    Publication date: January 29, 2015
    Inventors: Simone Schulzchen, Werner Purschke, Florian Jarosch, Kai Hohlig, Christian Maasch, Sven Klussmann
  • Publication number: 20150023968
    Abstract: An isolated DNA molecule comprising a fragment of the gene encoding the feline NIS is disclosed as well as methods of use thereof. Also provided are methods for rational diet design of food composition suitable for administration to feline companion animals afflicted with hyperthyroidism, comprising (a) accessing at least one database that comprises a first data set relating functional gene profile of a biofluid or tissue sample from an animal to physiological condition of the animal, where the functional gene profile is that of the feline NIS gene; (b) accessing at least one database that comprises a second data set relating effects of bioactive dietary components on the functional gene profile; (c) using an algorithm drawing on these data sets, processing input data defining physiological condition to derive a nutritional formula promoting wellness of a feline companion animal afflicted with hyperthyroidism; and (d) preparing a food composition based on the nutritional formula.
    Type: Application
    Filed: December 6, 2012
    Publication date: January 22, 2015
    Inventors: Samer Al-Murrani, Jeffrey Brockman
  • Publication number: 20150025220
    Abstract: The invention provides a compound of formula I: wherein R1-R6 and X have any of the values described herein, as well as pharmaceutical compostions comprising such compounds and therapeutic methods comprising the administration of such compounds.
    Type: Application
    Filed: July 21, 2014
    Publication date: January 22, 2015
    Inventor: Carston R. Wagner
  • Publication number: 20150024037
    Abstract: Compositions, methods of making, and methods of using, xenoantigen-displaying anticancer vaccines are described. In another broad aspect, there is provided herein a method of synthesizing an alkynefunctionalized composition of claim 1, comprising: deprotecting an ester comprising a Fmoc moiety to form a free acid; coupling the free acid of step (a) with an amine; and, removing the Fmoc moiety, and coupling the remaining moiety with palmitic acid to yield an alkyne-functionalized composition.
    Type: Application
    Filed: February 15, 2013
    Publication date: January 22, 2015
    Applicant: THE UNIVERSITY OF TOLEDO
    Inventors: Steven J. Sucheck, Katherine A. Wall, Sourav Sarkar
  • Publication number: 20150010592
    Abstract: The present invention encompasses a novel S. aureus bioconjugate vaccine. More generally, the invention is directed to Gram-positive and other bioconjugate vaccines containing a protein carrier, at least one polysaccharide such as a capsular Gram-positive polysaccharide, and, optionally, an adjuvant or pharmaceutically acceptable carrier. The instant invention also includes methods of producing Gram-positive and other bioconjugate vaccines. An N-glycosylated protein is also provided that contains one or more polysaccharides such as Gram-positive polysaccharides. The invention is additionally directed to engineered prokaryotic organisms comprising nucleotide sequences encoding a glycosyltransferase of a first prokaryotic organism and a glycosyltransferase of a second prokaryotic organism. The invention further includes plasmids and prokaryotic cells transformed with plasmids encoding polysaccharides and enzymes which produce an N-glycosylated protein and/or bioconjugate vaccine.
    Type: Application
    Filed: September 23, 2014
    Publication date: January 8, 2015
    Applicant: GLYCOVAXYN AG
    Inventors: Michael Wacker, Michael Kowarik, Michael Wetter
  • Publication number: 20140377178
    Abstract: The present invention relates to a method of labelling biological molecules with 18F, via attachment to fluorine to a macrocyclic metal complex of a non-radioactive metal, where the metal complex is conjugated to the biological molecule. Also provided are pharmaceutical compositions, kits and methods of in vivo imaging.
    Type: Application
    Filed: January 22, 2013
    Publication date: December 25, 2014
    Applicants: UNIVERSITY OF SOUTHAMPTON, GE HEALTHCARE LIMITED
    Inventors: Rajiv Bhalla, Sajinder Kaur Luthra, Gill Reid, I, William Levason
  • Publication number: 20140378652
    Abstract: The present invention relates to a method for preparing carbohydrate T cell epitope conjugates of formula (I): M(T-B)n(I) wherein M, T, B and n are as defined in claim 1.
    Type: Application
    Filed: March 16, 2012
    Publication date: December 25, 2014
    Applicants: Centre National de la Recherche Scientifique, Institut Pasteur
    Inventors: Sylvie Bay, Claude Leclerc, Richard Lo-Man
  • Publication number: 20140378326
    Abstract: This invention is directed to methods, kits, non-nucleotide probes as well as other compositions pertaining to the suppression of binding of detectable nucleic acid probes to undesired nucleotide sequences of genomic nucleic acid in assays designed to determine target genomic nucleic acid.
    Type: Application
    Filed: June 13, 2014
    Publication date: December 25, 2014
    Inventors: Kirsten NIELSON, Jens Hyldig-Nielsen, Brett F. Williams
  • Publication number: 20140371137
    Abstract: The present invention relates to methods and compositions pertaining to conjugates comprising a nucleic acid oligomer conjugated to a glucosamine or a derivative thereof which are useful for inhibiting the transcription of target nucleic acids. The conjugates of the invention exhibit advantageous bioavailability and readily penetrate cell membranes which make them useful for inhibiting translation of target mRNA in vivo.
    Type: Application
    Filed: June 13, 2014
    Publication date: December 18, 2014
    Inventors: Virendra Pandey, Jean-Luc Decout, Indrajit Das, Jerome Desire
  • Patent number: 8912310
    Abstract: The present disclosure describes environmentally responsive polypeptides capable of displaying stimuli-triggered conformational changes in a reversible or irreversible manner that may be accompanied by aggregation. Polypeptides include a number of repeated motifs and may be elastomeric or non-elastomeric. The polypeptides may be used to deliver therapeutics to a biological site and to develop bioactive polypeptides that are environmentally responsive.
    Type: Grant
    Filed: May 29, 2013
    Date of Patent: December 16, 2014
    Assignee: Duke University
    Inventors: Ashutosh Chilkoti, Felipe Garcia Quiroz
  • Patent number: 8911967
    Abstract: The present invention provides conjugates between peptides and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto either an amino acid or glycosyl residue on the peptide. Also provided are pharmaceutical formulations including the conjugates. Methods for preparing the conjugates are also within the scope of the invention.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: December 16, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Shawn DeFrees, David A. Zopf, Susann Taudte, Walter Scott Willett, Robert J. Bayer, Matthew Kalo